他汀类药物是目前最常用的降脂药物,除降脂作用外,还有改善血管内皮功能、抑制炎症反应、抗血小板聚集和稳定斑块等作用,在冠状动脉粥样硬化性心脏病整体防治中占重要地位。B类I型清道夫受体(scavenger receptor class B type I,SR-BI)...他汀类药物是目前最常用的降脂药物,除降脂作用外,还有改善血管内皮功能、抑制炎症反应、抗血小板聚集和稳定斑块等作用,在冠状动脉粥样硬化性心脏病整体防治中占重要地位。B类I型清道夫受体(scavenger receptor class B type I,SR-BI)是高密度脂蛋白的受体,两者协同参与胆固醇的逆向转运,在胆固醇清除中起重要作用,而且与动脉粥样硬化有着密切的关系。SRBI基因多态性可能对他汀类药物的疗效产生影响,现综述了他汀类药物与SR-BI及其基因多态性的关系。展开更多
Recent studies suggest that treatment with angiotensin Ⅱ type 1 (AT1) receptor blockers and lipid lowering agents, namely the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins may have ...Recent studies suggest that treatment with angiotensin Ⅱ type 1 (AT1) receptor blockers and lipid lowering agents, namely the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins may have beneficial effects on renal function independent of lowering actions on blood pressure and cholesterol.^(1,2) However, the renal effects of the combination of AT1 receptor blockers and statins in experimental diabetes are unknown. The aims of the present study were to determine whether valsartan and fluvastatin would lower the expression of nuclear factor kappa B ((NF-κB))and monocyte chemoattractant protein (MCP-1) in the tubulointerstitium and improve renal function and to see whether treatment with a combination of valsartan and fluvastatin would have any extra beneficial effect in streptozotocin (STZ)-induced unilaterally nephrectomized diabetic rats.展开更多
文摘他汀类药物是目前最常用的降脂药物,除降脂作用外,还有改善血管内皮功能、抑制炎症反应、抗血小板聚集和稳定斑块等作用,在冠状动脉粥样硬化性心脏病整体防治中占重要地位。B类I型清道夫受体(scavenger receptor class B type I,SR-BI)是高密度脂蛋白的受体,两者协同参与胆固醇的逆向转运,在胆固醇清除中起重要作用,而且与动脉粥样硬化有着密切的关系。SRBI基因多态性可能对他汀类药物的疗效产生影响,现综述了他汀类药物与SR-BI及其基因多态性的关系。
文摘Recent studies suggest that treatment with angiotensin Ⅱ type 1 (AT1) receptor blockers and lipid lowering agents, namely the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins may have beneficial effects on renal function independent of lowering actions on blood pressure and cholesterol.^(1,2) However, the renal effects of the combination of AT1 receptor blockers and statins in experimental diabetes are unknown. The aims of the present study were to determine whether valsartan and fluvastatin would lower the expression of nuclear factor kappa B ((NF-κB))and monocyte chemoattractant protein (MCP-1) in the tubulointerstitium and improve renal function and to see whether treatment with a combination of valsartan and fluvastatin would have any extra beneficial effect in streptozotocin (STZ)-induced unilaterally nephrectomized diabetic rats.
